

Case Study

Phase 2 To Determine Safety And Efficacy Of A mAB CKI Combo In Relapse Refractory Multiple Myeloma (RRMM)

Large Number of Assays Involvement, Adaptability, Partner - ships And Smooth Operations

Scope

Phase 2, open-label, multicenter
countries: 11
sites: 49
Regions: NA, EU

Cerba Research involved in ~300 routine & specialty assays/steps including immunophenotyping & PBMC isolation

Key Achievements

- ↑ 11,000+ samples managed to date
- ↑ Smooth trial operations
- ↑ Involved in complex & time consuming assays without breaking a sweat
- ↑ Involved early on from FIH to registration sponsor CART program
- ↑ Strong continued relationship

Timeline



Challenges

Cerba Research involved in ~300 tests/steps, such as multiparameter immunophenotyping FCM, PBMC isolation, CD138+cell isolation/count, FISH and much more

Solutions

- ↑ Frequent scientific discussions
- ↑ Flexibility in working with many lab partners (9 referral labs)

Cerba Research Data In-house (MSN F15); mAB=Monoclonal AntiBody; CKI=Checkpoint Inhibitor; RRMM=Relapsed or Refractory Multiple Myeloma; FPFV=First-Patient First-Visit; LPLV=Last-Patient Last-Visit; DBL=DataBase Lock FCM= Flow Cytometry PBMC= Peripheral Blood Mononuclear Cells FISH= Fluorescence In Situ Hybridization